Dr. Marty Makary, the commissioner of the Food and Drug Administration, is expected to resign from his position on Tuesday, according to a federal health official. This move comes after a tumultuous 13-month tenure marked by controversy and clashes with various groups. Makary’s resignation was reportedly prompted by pressure from the White House to authorize the sales of flavored e-cigarettes.
Makary’s time at the FDA was marked by significant challenges, including criticism from the Make America Healthy Again movement and those seeking a more traditional approach to regulation. He also faced opposition from groups disappointed by his approval of updated mRNA vaccines and a second generic version of mifepristone. The commissioner’s priorities often seemed to clash, leading to confusion and frustration within the pharmaceutical industry.
Leadership Change at the FDA
President Trump commented on the expected leadership change, stating that Makary is a “great guy” and a “wonderful man” who will do well in his future endeavors. However, the president’s remarks did not address the underlying issues that led to Makary’s resignation. The FDA’s decision-making process and regulatory predictability have been questioned during Makary’s tenure, particularly with regards to the approval of certain drugs and vaccines.
Makary’s background as a surgeon and health policy researcher at Johns Hopkins University School of Medicine did not seem to shield him from controversy. His criticism of vaccine policy and the Biden administration’s response to the COVID pandemic also sparked debate. The Senate confirmed Makary as FDA commissioner in March 2025, just before mass firings at the regulator left hundreds of positions vacant.
Implications and Future Directions
The resignation of Dr. Makary raises questions about the future of the FDA and its regulatory approach. The agency’s ability to balance the need for innovation with the need for safety and efficacy will be closely watched. The pharmaceutical industry, in particular, will be looking for signs of stability and predictability in the FDA’s decision-making process.
The FDA’s leadership change also highlights the challenges faced by regulatory agencies in balancing competing interests and priorities. As the agency moves forward, it will need to address the concerns of various stakeholders, including patients, industry leaders, and policymakers. The FDA’s ability to navigate these complexities will have significant implications for public health and the development of new treatments and therapies.
The resignation of Dr. Makary serves as a reminder of the importance of effective leadership and regulatory oversight in ensuring public health and safety. As the FDA embarks on a new chapter, it will be essential to prioritize transparency, accountability, and a commitment to science-based decision-making. The broader significance of this leadership change lies in its potential impact on the FDA’s ability to protect and promote public health, a critical function that affects the lives of millions of Americans.
